MA52747A - Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune - Google Patents
Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immuneInfo
- Publication number
- MA52747A MA52747A MA052747A MA52747A MA52747A MA 52747 A MA52747 A MA 52747A MA 052747 A MA052747 A MA 052747A MA 52747 A MA52747 A MA 52747A MA 52747 A MA52747 A MA 52747A
- Authority
- MA
- Morocco
- Prior art keywords
- ajisoindolylquinoline
- pyrazino
- tetrahydro
- compounds
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018090004 | 2018-06-05 | ||
EP18193916 | 2018-09-12 | ||
CN2019086019 | 2019-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52747A true MA52747A (fr) | 2021-04-14 |
Family
ID=66793968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052747A MA52747A (fr) | 2018-06-05 | 2019-06-03 | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune |
Country Status (19)
Country | Link |
---|---|
US (1) | US20210371432A1 (fr) |
EP (1) | EP3802539B1 (fr) |
JP (1) | JP7374130B2 (fr) |
KR (1) | KR20210018818A (fr) |
CN (1) | CN112204028B (fr) |
AU (1) | AU2019280728A1 (fr) |
BR (1) | BR112020024782A2 (fr) |
CA (1) | CA3098291A1 (fr) |
CL (1) | CL2020003065A1 (fr) |
CO (1) | CO2020014677A2 (fr) |
CR (1) | CR20200584A (fr) |
IL (1) | IL279144A (fr) |
MA (1) | MA52747A (fr) |
MX (1) | MX2020012827A (fr) |
PE (1) | PE20210131A1 (fr) |
PH (1) | PH12020552092A1 (fr) |
SG (1) | SG11202011137SA (fr) |
TW (1) | TW202016111A (fr) |
WO (1) | WO2019233941A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4058452A1 (fr) * | 2019-11-12 | 2022-09-21 | F. Hoffmann-La Roche AG | Composés d'hydropyrazino[1,2-b]isoquinoline pour le traitement d'une maladie auto-immune |
JP2023502087A (ja) * | 2019-11-19 | 2023-01-20 | エフ.ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のためのヒドロ-1H-ピロロ[1,2-a]ピラジン化合物 |
CN114667286A (zh) * | 2019-11-19 | 2022-06-24 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的三氮杂三环类化合物 |
EP4182032A1 (fr) | 2020-07-14 | 2023-05-24 | F. Hoffmann-La Roche AG | Composés d'hydroisoquinoline ou d'hydronaphtyridine pour le traitement d'une maladie auto-immune |
TW202214632A (zh) * | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
CN114057759B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 稠合四环类衍生物、其制备方法及其在医药上的应用 |
MX2023006193A (es) | 2020-11-26 | 2023-06-09 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto triciclico fusionado, metodo de preparacion y aplicacion del mismo en medicina. |
WO2023025109A1 (fr) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | Inhibiteur du récepteur de type toll et sa préparation et son application |
CN114656363A (zh) * | 2022-03-28 | 2022-06-24 | 南京林业大学 | 一种钯催化芳香酯类化合物的合成方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011106276A1 (fr) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Antagonistes des canaux task |
TWI702218B (zh) * | 2013-10-14 | 2020-08-21 | 日商衛材R&D企管股份有限公司 | 選擇性經取代之喹啉化合物 |
CA3005766A1 (fr) * | 2015-12-17 | 2017-06-22 | Merck Patent Gmbh | Antagonistes de tlr7/8 polycyliques et leur utilisation dans le traitement de maladies immunes |
JP7125385B2 (ja) * | 2016-08-08 | 2022-08-24 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Tlr7/8アンタゴニストおよびそれらの使用 |
-
2019
- 2019-06-03 WO PCT/EP2019/064323 patent/WO2019233941A1/fr unknown
- 2019-06-03 PE PE2020001875A patent/PE20210131A1/es unknown
- 2019-06-03 JP JP2020567772A patent/JP7374130B2/ja active Active
- 2019-06-03 KR KR1020207034855A patent/KR20210018818A/ko unknown
- 2019-06-03 BR BR112020024782-0A patent/BR112020024782A2/pt not_active Application Discontinuation
- 2019-06-03 CA CA3098291A patent/CA3098291A1/fr active Pending
- 2019-06-03 MX MX2020012827A patent/MX2020012827A/es unknown
- 2019-06-03 EP EP19729220.4A patent/EP3802539B1/fr active Active
- 2019-06-03 CR CR20200584A patent/CR20200584A/es unknown
- 2019-06-03 AU AU2019280728A patent/AU2019280728A1/en not_active Abandoned
- 2019-06-03 US US16/972,556 patent/US20210371432A1/en active Pending
- 2019-06-03 SG SG11202011137SA patent/SG11202011137SA/en unknown
- 2019-06-03 MA MA052747A patent/MA52747A/fr unknown
- 2019-06-03 CN CN201980035182.7A patent/CN112204028B/zh active Active
- 2019-06-04 TW TW108119369A patent/TW202016111A/zh unknown
-
2020
- 2020-11-25 CL CL2020003065A patent/CL2020003065A1/es unknown
- 2020-11-26 CO CONC2020/0014677A patent/CO2020014677A2/es unknown
- 2020-12-01 IL IL279144A patent/IL279144A/en unknown
- 2020-12-04 PH PH12020552092A patent/PH12020552092A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112020024782A2 (pt) | 2021-03-02 |
EP3802539B1 (fr) | 2023-09-20 |
CL2020003065A1 (es) | 2021-04-30 |
JP7374130B2 (ja) | 2023-11-06 |
EP3802539C0 (fr) | 2023-09-20 |
IL279144A (en) | 2021-01-31 |
PE20210131A1 (es) | 2021-01-19 |
CR20200584A (es) | 2021-01-18 |
EP3802539A1 (fr) | 2021-04-14 |
AU2019280728A1 (en) | 2020-11-12 |
PH12020552092A1 (en) | 2021-05-31 |
SG11202011137SA (en) | 2020-12-30 |
CN112204028A (zh) | 2021-01-08 |
MX2020012827A (es) | 2021-02-15 |
KR20210018818A (ko) | 2021-02-18 |
CN112204028B (zh) | 2023-12-29 |
WO2019233941A1 (fr) | 2019-12-12 |
CA3098291A1 (fr) | 2019-12-12 |
JP2021527041A (ja) | 2021-10-11 |
TW202016111A (zh) | 2020-05-01 |
US20210371432A1 (en) | 2021-12-02 |
CO2020014677A2 (es) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
MA53661A (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
MA55594A (fr) | Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune | |
MA49402A (fr) | Polynucléotides aadc pour le traitement de la maladie de parkinson | |
MA55214A (fr) | Composés, compositions et procédés pour le traitement d'une maladie | |
FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
MA45052A (fr) | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille | |
MA49131A (fr) | Utilisation d'antagonistes de klk5 pour le traitement d'une maladie | |
MA55974A (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
MA52631A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA44864A (fr) | Trithérapie pour le traitement d'une maladie intestinale inflammatoire | |
MA51738A (fr) | Composés pour le traitement de la douleur | |
MA54544A (fr) | Inhibiteurs de la voie jak1 pour le traitement d'une maladie gastro-intestinale | |
MA55199A (fr) | Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie | |
MA53268A (fr) | Mini-gde pour le traitement de la maladie de stockage du glycogène iii | |
MA47395A (fr) | Méthode pour le traitement d'une maladie neurologique | |
FR2915398B1 (fr) | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" | |
MA55148A (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
MA53739A (fr) | Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés | |
MA53252A (fr) | Thérapie génique non perturbatrice pour le traitement d'un mma | |
MA54792A (fr) | Compositions et méthodes pour le traitement de la maladie de parkinson | |
MA55973A (fr) | Composé pour le traitement de la goutte ou de l'hyperuricémie | |
MA53562A (fr) | Polythérapie destinée au traitement d'une maladie hépatique | |
MA56186A (fr) | Composés pour le traitement d'une maladie respiratoire |